Comparison of Holmium Laser Enucleation of the Prostate and Robotic Water Jet Ablation for Benign Prostatic Hyperplasia
Prospective Randomized Controlled Comparison of Holmium Laser Enucleation of the Prostate With Robotic Water Jet Ablation
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
This prospective, randomized controlled trial is designed to compare the safety, effectiveness, and long-term durability of Holmium Laser Enucleation of the Prostate (HoLEP) utilizing MOSES 2.0 technology with Robotic Water Jet Ablation (RWJA) performed using the Hydros Robotic System for the treatment of benign prostatic hyperplasia (BPH). The trial will enroll 100 men aged 50 to 80 years who present with moderate-to-severe lower urinary tract symptoms secondary to BPH and prostate volumes between 50 and 180 mL. Participants will be randomized in a 1:1 ratio to receive either HoLEP or RWJA and will be monitored for five years following treatment.
The primary objective is to compare objective measures of treatment efficacy and durability at 12 months, specifically changes in prostate volume, prostate-specific antigen (PSA) levels, urinary flow rate (Qmax), and post-void residual urine volume (PVR). Secondary objectives include assessment of perioperative outcomes, safety profiles, patient-reported urinary and sexual function, treatment durability, reintervention rates, and healthcare resource utilization. Outcomes will be measured using validated instruments, such as the International Prostate Symptom Score (IPSS), Sexual Health Inventory for Men (SHIM), Male Sexual Health Questionnaire-Ejaculatory Dysfunction (MSHQ-EjD), and Incontinence Severity Index (ISI).
Although both procedures are established and FDA-approved therapies for BPH, direct comparative evidence is limited. This study seeks to address this evidence gap by generating high-quality comparative effectiveness data to inform clinical decision-making and patient counseling. The results may clarify the relative benefits and tradeoffs of each procedure, particularly in terms of symptom improvement, preservation of sexual function, durability of treatment response, and long-term healthcare utilization.
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: Hazem Elmansy, MD
- Número de telefone: 346-516-1481
- E-mail: hmelmansy@houstonmethodist.org
Estude backup de contato
- Nome: Miguel Valdivia y Alvarado, MD
- Número de telefone: 346-356-3622
- E-mail: mvaldiviayalvarado@houstonmethodist.org
Locais de estudo
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- Houston Methodist
-
Contato:
- Hazem Elmansy, MD
- Número de telefone: 346-516-1481
- E-mail: hmelmansy@houstonmethodist.org
-
Contato:
- Miguel Valdivia y Alvarado, MD
- Número de telefone: 346-356-3622
- E-mail: mvaldiviayalvarado@houstonmethodist.org
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Male, age 50-80 years
- International Prostate Symptom Score (IPSS) ≥ 12
- Prostate size (TRUS): 50-180 mL
- Diagnosis of LUTS due to BPH
- Uroflow Qmax ≤ 15 mL/sec
- Mentally capable, able to comply with study procedures, written informed consent provided
- Able to follow study instructions and complete all required visits
Exclusion Criteria:
- BMI ≥ 42
- History of prostate cancer
- Suspected or history of bladder cancer
- Active or untreated bladder stones at screening
- Indwelling catheter for more than 3 months before baseline
- Active urinary tract infection
- History of urethral stricture or bladder neck stenosis
- Damage to the external urethral sphincter
- Previous prostate surgery or lower urinary tract surgery
- Use of obligatory anticoagulants (if not stoppable) or known coagulopathy (except ASA 100 mg/d)
- Contraindications to general and spinal anesthesia
- Any condition that could interfere with study participation or outcomes, per investigator judgment
- Lacks legal or mental capacity to consent
- Simultaneous participation in another therapeutic urological trial
- Known or persistent abuse of medication, drugs, or alcohol
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Outro
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Comparador Ativo: HoLEP with MOSES 2.0
Holmium laser enucleation of the prostate using MOSES 2.0 pulse-modulation technology, performed per institutional standard of care.
|
Holmium laser enucleation of the prostate using MOSES 2.0 pulse-modulation technology, performed per institutional standard of care.
|
|
Comparador Ativo: RWJA with Hydros Robotic System
Robotic-assisted waterjet ablation of the prostate using the Hydros Robotic System, performed per institutional standard of care.
|
Device - RWJA (Hydros Robotic System) / Aquablation therapy (often referred to by its commercial name, "Aquablation").
|
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in Prostate Volume
Prazo: Baseline and 12 months post-intervention
|
Measured via transrectal ultrasound (TRUS); change from baseline.
|
Baseline and 12 months post-intervention
|
|
Change in Prostate-Specific Antigen (PSA)
Prazo: Baseline and 12 months post-intervention
|
Serum PSA level; change from baseline.
|
Baseline and 12 months post-intervention
|
|
Change in Urinary Flow Rate (Qmax)
Prazo: Baseline and 12 months post-intervention
|
Peak urinary flow rate via uroflowmetry; change from baseline.
|
Baseline and 12 months post-intervention
|
|
Change in Post-Void Residual Volume (PVR)
Prazo: Baseline and 12 months post-intervention
|
Bladder scan-measured PVR; change from baseline.
|
Baseline and 12 months post-intervention
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Incidence and Severity of Adverse Events
Prazo: From patient hospital discharge through 3 and 12 months post-surgery
|
Adverse events graded by the Clavien-Dindo classification system.
|
From patient hospital discharge through 3 and 12 months post-surgery
|
|
Operative Time
Prazo: Day (duration) of surgical procedure
|
Total procedure time, start to finish.
|
Day (duration) of surgical procedure
|
|
Hemostasis Time
Prazo: Day (duration) of surgical procedure
|
Time required to achieve hemostasis intraoperatively.
|
Day (duration) of surgical procedure
|
|
Perioperative Change in Hemoglobin
Prazo: Baseline to immediate postoperative period (when patient is in the recovery room post surgery)
|
Hemoglobin level change from baseline to immediate postoperative measurement.
|
Baseline to immediate postoperative period (when patient is in the recovery room post surgery)
|
|
Time to Catheter-Free Status
Prazo: From surgery day until catheter removal
|
Duration from end of surgery to catheter removal.
|
From surgery day until catheter removal
|
|
Length of Hospital Stay / Discharge Time
Prazo: Day of surgical procedure through hospital discharge
|
Time from surgery to hospital discharge.
|
Day of surgical procedure through hospital discharge
|
|
Change in IPSS/QoL Score
Prazo: Baseline, 3, 6, and 12 months post-surgery
|
International Prostate Symptom Score / Quality of Life index.
|
Baseline, 3, 6, and 12 months post-surgery
|
|
Change in SHIM Score
Prazo: Baseline, 3, 6, and 12 months post-surgery
|
Sexual Health Inventory for Men.
|
Baseline, 3, 6, and 12 months post-surgery
|
|
Change in MSHQ-EjD Score
Prazo: Baseline, 3, 6, and 12 months post-surgery
|
Male Sexual Health Questionnaire - Ejaculatory Dysfunction.
|
Baseline, 3, 6, and 12 months post-surgery
|
|
Change in Incontinence Outcomes
Prazo: Baseline, 3, 6, and 12 months post-surgery
|
Incontinence Severity Index (ISI) score and Cough Stress Test (CST) result.
|
Baseline, 3, 6, and 12 months post-surgery
|
|
Long-Term Durability of Functional Improvements
Prazo: 24, 36, 48, and 60 months post-intervention
|
Composite tracking of IPSS, Qmax, PVR, PSA, and prostate volume.
|
24, 36, 48, and 60 months post-intervention
|
|
Post-Operative Medication Use
Prazo: Through 60 months post-intervention
|
Number of prescriptions written and filled (initial fills and refills), e.g., alpha-blockers, 5-alpha reductase inhibitors.
|
Through 60 months post-intervention
|
|
Reintervention Rate
Prazo: Through 60 months post-intervention
|
Repeat procedures or additional therapies for BPH/LUTS.
|
Through 60 months post-intervention
|
|
Unplanned Healthcare Encounters
Prazo: Through 60 months post-intervention
|
Emergency visits, urgent care visits, and add-on clinic visits related to the procedure.
|
Through 60 months post-intervention
|
|
Incidence of Urethral Stricture Requiring Intervention
Prazo: Through 60 months post-intervention
|
New urethral stricture or bladder neck stenosis requiring treatment.
|
Through 60 months post-intervention
|
|
Unanticipated Advanced Diagnostics
Prazo: Through 60 months post-intervention
|
Unplanned MRI, cystoscopy, or prostate cancer biomarker testing.
|
Through 60 months post-intervention
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
Outros números de identificação do estudo
- Pro00041304
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .